Cellect Biotechnology Ltd. (Nasdaq: APOP) announced the first successful stem cell transplant procedure using its ApoGraft technology in a Phase I/II clinical trial. The stock price leaped $4.64 to close at $10.90..
First successful transplant for Cellect Biotechnology
March 27, 2017 at 18:04 PM EDT
